每经记者｜许立波 每经编辑｜张益铭 在中国创新药的投资热情空前高涨之际，一款曾因"国人自主研发的抗阿尔茨海默病新药"而名噪一时的 明星产品"九期一"，正陷入停产风波。 在位于青浦的"绿谷生命园"，记者发现虽有少数员工仍在岗，但现场同样未见明显生产活动。在持续数 小时的观察中，记者仅见到一辆医药冷链运输车进出厂区。在与现场一位员工攀谈时，他告诉记 者："该厂区还在做药，并未停工。" 绿谷制药位于上海浦东的生产基地项目投资合计12.27亿元，本应于2024年底前完成验收并投入运行。 但现场一位员工却告诉记者，该基地自大楼落成以来就没有真正投入使用。"厂子建好后就空着了，没 见有生产过，也没装修。" 对此，王慧向记者确认称，青浦基地确实仍在运转，但主要承担的是丹参多酚酸盐原料及制剂的生 产，"九期一"的相关产线已经停产。浦东生产基地自建成后未投入使用"确实是因为'九期一'的注册证延 期、叠加公司目前的资金困难，导致项目处于停滞状态"。 她还表示，目前监管机构尚未给出明确答复，但企业一直在积极沟通，今年3月、4月去北京参加了专家 评审会并答辩。 在谈到公司将如何纾困解难时，王慧表示："我们还是希望通过完成手头的相关工 ...

Core Viewpoint - The drug Gantoret Sodium Capsule (brand name: Jiuyi) for Alzheimer's disease has become scarce, leading to widespread concern about the difficulties patients face in obtaining medication [2][4][5] Group 1: Supply Issues - Since 2025, Gantoret Sodium Capsule has faced prescription difficulties in hospitals and supply shortages on online platforms [4][5] - The manufacturer, Green Valley Pharmaceutical Technology, acknowledged the supply issues and is in communication with relevant authorities to address the situation [2][4] - Reports indicate that the drug's market price has increased by approximately 40% in recent months, with some pharmacies listing prices as high as 5000 yuan per box [5][6] Group 2: Market Dynamics - The drug was first approved for conditional listing in November 2019 and officially launched in December 2019, allowing patients to purchase it with a doctor's prescription [4][6] - The initial price of the drug was set at 895 yuan per box, but it was later included in the national medical insurance directory, reducing the price to 296 yuan per box [6][7] - The current monthly cost for patients using Gantoret Sodium is approximately 1184 yuan, significantly lower than the combined cost of traditional treatments [6][7] Group 3: Disease Context - Alzheimer's disease is a major neurodegenerative condition affecting over 55 million people globally, with China having the highest number of patients [8] - The treatment options for Alzheimer's disease are limited, with Gantoret Sodium being one of the few drugs that can improve cognitive function without worsening the condition [8][9] - The drug was conditionally approved due to the urgent need for treatment options, despite some initial concerns regarding long-term safety data [9]